These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 6144063)

  • 1. Effects of apomorphine, TL-99 and 3-PPP on yawning in rats.
    Mogilnicka E; Boissard CG; Delini-Stula A
    Neuropharmacology; 1984 Jan; 23(1):19-22. PubMed ID: 6144063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of dopamine autoreceptor agonist properties of apomorphine, (+)-3-PPP and (-)-3-PPP by recording of yawning behaviour in rats.
    Ståhle L; Ungerstedt U
    Eur J Pharmacol; 1984 Feb; 98(2):307-10. PubMed ID: 6714314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological profiles of the putative dopamine autoreceptor agonists 3-PPP and TL-99.
    Martin GE; Haubrich DR; Williams M
    Eur J Pharmacol; 1981 Nov; 76(1):15-23. PubMed ID: 7318920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different actions of TL-99 and 3-PPP in producing contraversive turning in the 6-OHDA-lesioned rat.
    Martin GE; Jones JH; Bendesky RJ
    Eur J Pharmacol; 1983 Sep; 92(3-4):275-8. PubMed ID: 6138266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of apomorphine-induced yawning in rats by the dopamine autoreceptor antagonist (+)-AJ 76.
    Dourish CT; Herbert EN; Iversen SD
    Neuropharmacology; 1989 Dec; 28(12):1423-5. PubMed ID: 2615920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apomorphine-induced penile erection and yawning: site of action in brain.
    Melis MR; Argiolas A; Gessa GL
    Brain Res; 1987 Jul; 415(1):98-104. PubMed ID: 3497688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative selectivity of 6,7-dihydroxy-2-dimethylaminotetralin, N-n-propyl-3-(3-hydroxyphenyl)piperidine, N-n-propylnorapomorphine and pergolide as agonists at striatal dopamine autoreceptors and postsynaptic dopamine receptors.
    Claustre Y; Fage D; Zivkovic B; Scatton B
    J Pharmacol Exp Ther; 1985 Feb; 232(2):519-25. PubMed ID: 2857197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The yawning-penile erection syndrome as a model for putative dopamine autoreceptor activity.
    Gower AJ; Berendsen HG; Princen MM; Broekkamp CL
    Eur J Pharmacol; 1984 Aug; 103(1-2):81-9. PubMed ID: 6479232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Avoidance and ICSS behavioral models dissociate TL-99 and 3-PPP from dopamine receptor antagonists.
    Fenton HM; Hall NR; Gerhardt S; Noreika L; Neale R; Liebman JM
    Eur J Pharmacol; 1983 Aug; 91(4):421-30. PubMed ID: 6617749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modification of apomorphine-, physostigmine- and pilocarpine-induced yawning after long-term treatment with neuroleptic or cholinergic agents.
    Ushijima I; Noda Y; Mizuki Y; Yamada M
    Arch Int Pharmacodyn Ther; 1984 Oct; 271(2):180-8. PubMed ID: 6150689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of central beta-adrenoceptors in the regulation of yawning responses.
    Yamada K; Matsumoto S; Nagashima M; Kumagai M; Kimura H; Furukawa T
    Naunyn Schmiedebergs Arch Pharmacol; 1989 Jul; 340(1):26-30. PubMed ID: 2571945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biphasic effects of some dopamine agonists on striatal acetylcholine concentrations.
    Waldmeier PC
    Eur J Pharmacol; 1983 May; 90(1):115-20. PubMed ID: 6873173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of cholinergic and dopaminergic influences on yawning behavior.
    Holmgren B; Urbá-Holmgren R
    Acta Neurobiol Exp (Wars); 1980; 40(3):633-42. PubMed ID: 6969021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-synaptic 5-HT1A receptor involvement in yawning and penile erections induced by apomorphine, physostigmine and mCPP in rats.
    Protais P; Windsor M; Mocaër E; Comoy E
    Psychopharmacology (Berl); 1995 Aug; 120(4):376-83. PubMed ID: 8539317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of yawning behavior induced by apomorphine, physostigmine and pilocarpine.
    Ushijima I; Mizuki Y; Imaizumi J; Yamada M; Noda Y; Yamada K; Furukawa T
    Arch Int Pharmacodyn Ther; 1985 Feb; 273(2):196-201. PubMed ID: 4004417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct evidence for involvement of dopaminergic inhibition and cholinergic activation in yawning.
    Yamada K; Furukawa T
    Psychopharmacology (Berl); 1980 Jan; 67(1):39-43. PubMed ID: 6768077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presynaptic dopaminergic agonists modify brain glucose metabolism in a way similar to the neuroleptics.
    Palacios JM; Wiederhold KH
    Neurosci Lett; 1984 Sep; 50(1-3):223-9. PubMed ID: 6149502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of catecholamine receptor activities in modulating the incidence of yawning in rats.
    Kimura H; Yamada K; Nagashima M; Furukawa T
    Pharmacol Biochem Behav; 1996 Apr; 53(4):1017-21. PubMed ID: 8801573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Muscarinic and nicotinic effects on yawning and tongue protruding in the rat.
    Ushijima I; Yamada K; Inoue T; Tokunaga T; Furukawa T; Noda Y
    Pharmacol Biochem Behav; 1984 Aug; 21(2):297-300. PubMed ID: 6541344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of the putative dopamine autoreceptor agonists 3-PPP and TL-99 with [3H]apomorphine binding sites in rat striatal membranes.
    Williams M; Totaro JA
    Eur J Pharmacol; 1982 Dec; 86(1):35-42. PubMed ID: 7160432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.